2 results
Approved WMOPending
The primary objective of this study is to assess whether tacrolimus is effective for the treatment of morphea.
Approved WMORecruiting
To compare the 120 mg once daily (QD) dose and 200 mg QD dose of MK*6482with respect to objective response rate (ORR) based on Response Criteria in Solid Tumors (RECIST) 1.1 as assessed by blinded independent central review (BICR).